[Line Items] for Business Acquisition, Pro Forma Information

No definition available.

Name:	mnk_BusinessAcquisitionProFormaInformationLineItems
Namespace Prefix:	mnk_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name:	us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.

+ References

+ Details

Name:	us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.

+ References

+ Details

Name:	us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.

+ References

+ Details

Name:	us-gaap_BusinessAcquisitionsProFormaRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

+ Details

Name:	us-gaap_DebtInstrumentInterestRateEffectivePercentage
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_DebtInstrumentAxis=mnk_A2020NotesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=mnk_IkariaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=mnk_A2025NotesMemberMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=us-gaap_RevolvingCreditFacilityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=mnk_NewTermLoanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=mnk_QuestcorPharmaceuticalsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=mnk_TermLoanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=mnk_CadencePharmaceuticalsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Acquisitions and License Agreements (Schedule of Unaudited Pro Forma Information) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Jun. 26, 2015	Jun. 27, 2014	Jun. 26, 2015	Jun. 27, 2014	Apr. 16, 2015	Aug. 14, 2014	Mar. 19, 2014
Business Acquisition, Pro Forma Information [Line Items]
Net sales, pro forma	$ 982.1	$ 1,033.5	$ 2,964.8	$ 2,870.0
Net (loss) income, pro forma	$ 81.1	$ 56.6	$ 264.2	$ 99.5
Basic (loss) earnings per share, pro forma (in usd per share)	$ 0.70	$ 0.53	$ 2.29	$ 0.93
Diluted (loss) earnings per share, pro forma (in usd per share)	$ 0.69	$ 0.52	$ 2.26	$ 0.92
2020 Notes \| Unsecured Debt \| Ikaria, Inc.
Business Acquisition, Pro Forma Information [Line Items]
Interest rate					4.875%
2025 Notes \| Unsecured Debt \| Ikaria, Inc.
Business Acquisition, Pro Forma Information [Line Items]
Interest rate					5.50%
Revolving Credit Facility \| Unsecured Debt \| Ikaria, Inc.
Business Acquisition, Pro Forma Information [Line Items]
Interest rate					3.00%
New Term Loan \| Secured Debt
Business Acquisition, Pro Forma Information [Line Items]
Interest rate	3.50%		3.50%
New Term Loan \| Secured Debt \| Questcor Pharmaceuticals, Inc.
Business Acquisition, Pro Forma Information [Line Items]
Interest rate						3.50%
Term Loan \| Secured Debt
Business Acquisition, Pro Forma Information [Line Items]
Interest rate	3.25%		3.25%
Term Loan \| Secured Debt \| Cadence Pharmaceuticals, Inc.
Business Acquisition, Pro Forma Information [Line Items]
Interest rate							3.50%